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Abstract: Cartilage is frequently injured but shows little capacity for repair. Current treatment options include the use of 
procedures that stimulate repair through the stimulation of subchondral bone marrow and result in the formation of 
fibrocartilage. There is considerable interest in the use of cell-based treatment strategies and there are limited studies 
describing the use of mesenchymal stem cells for cartilage repair with promising early results. This paper reviews the 
current treatment strategies for articular cartilage, describes use of mesenchymal stem cells for articular cartilage repair 
along with the results of clinical studies, and describes the future direction that these strategies are likely to take. 
Keywords: Cartilage repair, chondrogenesis, mesenchymal stem cells, osteoarthritis, tissue engineering. 
  Hyaline articular cartilage is a highly specialized tissue. 
It is characteristically avascular and depends on diffusion 
from cyclical loading during joint movement for nutrient 
acquisition [1]. As well as its shock absorbing function it 
enables synovial joints to articulate with extremely low 
frictional forces. Despite the best efforts of man to engineer 
smooth bearing surfaces, prosthetic joints cannot recreate 
anything like the low frictional environment of native 
synovial joints. 
  However articular cartilage does not readily repair itself 
following injury [2]. With pure chondral injuries the absence 
of a direct blood supply means that progenitor cells cannot 
reach the injured areas. Neither do surrounding chondrocytes 
migrate into cartilage defects and produce a reparative 
matrix. Repair relies on the mitotic potential of chondrocytes 
and a short lived increase in metabolic products, chiefly 
collagen and proteoglycans. However chondrocytes have low 
mitotic potential in vivo [3]. There is however some attempt 
at repair when cartilage damage breaches the underlying 
subchondral bone (osteochondral lesions). A primitive 
mesenchymal blood clot forms leading to the production of 
fibrocartilage [4]. This fibrocartilage has inferior 
biomechanical properties to hyaline cartilage and is the basis 
for marrow stimulation techniques such as microfracture. 
  Small cartilage defects can develop into widespread 
osteoarthritis, a particularly difficult problem to treat in the 
younger age group not suitable for fusion or joint 
replacement. Subsequently research interest into cartilage 
repair has been vast. A variety of methods have been 
developed in an attempt to repair articular cartilage defects. 
None are perfect. These include bone marrow stimulation 
techniques (subchondral drilling, abrasion, microfracture),   
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osteochondral grafting (mosaicplasty) and autologous 
chondrocyte implantation (ACI). Recently autologous 
chondrocytes have been cultured on collagen membranes 
prior to re- implantation, a technique known as MACI 
(matrix assisted autologous chondrocyte implantation). 
  These procedures are limited to small and medium sized 
focal chondral and osteochondral defects. Mosaicplasty is 
limited by the need to create defects at donor sites, by poor 
healing between the grafts, and by difficulty in recreating the 
natural curvature of the joint. The ACI technique was first 
performed by Peterson et al. in 1994 [5] in Sweden. 
Although good results have been reported with ACI the 
quantity of harvested chondrocytes from non-weight bearing 
areas of cartilage is limited, and chondrocytes can 
dedifferentiate into fibroblasts when cultured in vivo. In 
addition harvested chondrocytes taken from already 
damaged joints may already be starting to show signs of 
degradation [6]. 
  There is no evidence that the above techniques can 
reliably produce long lasting, durable articular cartilage. 
  An alternative, easily obtainable cell source with stable 
chondrocyte potential becomes necessary. 
ALTERNATIVE SOURCES OF CHONDROCYTES 
  There are a number of chondroprogenitor cell pools 
within adult mammalian organisms that have the potential to 
differentiate into chondrocytes and form mature cartilage 
tissue. These include cells within the cambial layers of the 
perichondrium and periosteum, the synovial membrane, 
adipose tissue, muscle and the bone marrow stroma. 
Classically, stem cells are defined by their capacity to remain 
an undifferentiated state for a prolonged period while 
retaining the potential to differentiate along one lineage 
(unipotent), multiple lineages (multipotent), or into all three 
germ layers (pluripotent) [7]. Stem Cells and Cartilage Repair  The Open Orthopaedics Journal, 2011, Volume 5    297 
  Embryonic stem cells (ESCs) have been shown to 
differentiate into a variety of tissues, including cartilage [8]. 
They are harvested from the inner cell mass of the blastocyst 
and are pluripotent cells. However while ESCs have 
significant regeneration capacity, their clinical application 
has been limited due to several factors including concerns 
about teratoma formation, host immune rejection and the 
obvious ethical issues involved. 
  Adult stem cells have also been identified. They are 
categorized as either hemopoietic or nonhemopoietic 
depending on which cell lineages they have the potential to 
differentiate into. Nonhaemopoietic stem cells can give rise 
to cells of mesenchymal origin including bone, cartilage, 
muscle and adipose tissue. They are further characterized by 
an ability to adhere to plastic and the expression of specific 
surface antigens which allows their identification in vitro. 
These mesenchymal stem cells (MSCs) can be isolated from 
various tissues including blood, adipose, skin, mandible, 
trabecular bone and even the umbilical cord and placenta. 
Amongst the various sources, MSCs isolated from the bone 
marrow are considered to have the greatest potential for 
multilineage differentiation and have been the most 
characterized since their discovery in the early 1970s by 
Friedenstein [9]. However harvesting of bone marrow is 
painful and not without the potential for complications. 
Hence an alternative easily obtainable source of cells with a 
small risk of complications would be ideal. Due to ease of 
harvest and abundance, adipose derived mesenchymal cells 
have become increasingly popular for use in many stem cell 
applications [10]. 
  Another unique source of multipotent cells arises from 
Wharton’s jelly in human umbilical cords [11]. 
  Adult mesenchymal stem cells are easily obtainable in 
high numbers and expandable in vitro without losing their 
differentiation potential. Owing to their stem cell-like 
properties they are fairly well tolerated immunologically. 
Hence allogenic cells could be made readily available on a 
commercial basis avoiding the need for iliac crest bone 
marrow biopsies. 
  Although there have been some studies looking at direct 
application of these cells to cartilage defects most 
investigators have tried to use MSCs to engineer articular 
cartilage in vitro. 
CHONDROGENIC DIFFERENTIATION OF STEM 
CELLS 
  It follows that the healing response seen in naturally 
ocurring full thickness cartilage defects is likely due to 
mesenchymal stem cells from the bone marrow entering the 
injured area via the blood vessels in the subchondral bone. 
However this repair is known to be incomplete and mainly 
composed of fibrocartilage [4]. Why is this? Caplan et al. 
[12] postulated that the number of progenitor cells in whole 
marrow aspirates was too low for effective cartilage 
production. They thus isolated and culture expanded MSCs 
from marrow aspirates before transplantation, with much 
better results in animal models. 
  It is also important to remember that hyaline cartilage is 
formed of several different cell layers. The uppermost layer 
is formed by articular chondrocytes progressing to 
hypertrophic chondrocytes and underlying subchondral bone. 
Caplan  et al. [12] in a rabbit model observed that 
mesenchymal stem cells transplanted into full thickness 
cartilage defects could recreate this layered arrangement. 
Detailed analysis showed that the implanted cells followed 
the embryonic sequence. Initially the cells rapidly 
differentiated into embryonic cartilage. Chondrocytes at the 
defect base then differentiate into hypertrophic chondrocytes 
which are subsequently replaced by vascalature and host 
osteoblasts leading to the production of new subchondral 
bone. The top cartilage remained as articular cartilage 
probably from exposure to synovial factors. 
TISSUE ENGINEERED APPROACHES TO 
CARTILAGE REPAIR 
  Tissue engineering can be defined as the art of 
reconstituting mammalian tissues, both structurally and 
functionally [13]. The process can be conducted either 
entirely or partly in vitro with the engineered tissues then 
transplanted into articular cartilage defects. There are 
essentially four main components required for successful 
tissue engineering. Firstly a physical scaffold to provide an 
adequate three-dimensional surrounding for handling. 
Secondly, appropriate cells which are able to differentiate 
and maintain the specific cell phenotype. Thirdly, the 
addition of the right bioactive substances such as growth 
factors, cytokines or hormones as a suitable stimulus for 
specific lineage differentiation of the cells. Finally the 
tissues need to be able to withstand the mechanical and 
biochemical environment into which they are placed. 
  Specifically related to repair of articular cartilage repair 
an available cell population is needed which can meet the 
metabolic demands of restoring a functional extracellular 
matrix. This can be accomplished with either fully 
differentiated chondrocytes, mesenchymal stem cells, or 
gene transduced cells. As well as an appropriate scaffold to 
fill the void of the defect a method is also needed for 
adequate internal fixation of the implant or cell based graft 
within the synovial environment. Fixation must be able to 
withstand the forces of joint motion but must not interfere 
with the repair process. 
  Using these principles autologous bone marrow stromal 
cells have been used for the repair of full-thickness articular 
cartilage defects in humans, resulting in stable fibrocartilage 
tissue formation at the defect site [14, 15]. However it is 
likely that in order to repair cartilage defects with a stable 
hyaline-rich tissue the delivery of factors stimulating 
chondrogenesis and maintenance of the articular cartilage 
phenotype needs to be more efficient than purely exogenous 
administration. 
GENE-ENHANCED TISSUE ENGINEERING 
  The application of gene transfer to articular cartilage was 
pioneered by Evans and co-workers as a means to treat 
arthritis [16]. Essentially these techniques aim to program 
cells to produce bioactive factors to promote their 
specialized functions. An example would be isolating the 
gene for bone morphogenetic protein (BMP) and introducing 
it into primary periosteal cells, thereby encouraging the 
osteogenic and chondrogenic capabilities of the cells. 
Therapeutic genes can be delivered to the synovium or 298    The Open Orthopaedics Journal, 2011, Volume 5  Punwar and Khan 
directly to the cartilage lesion. Gene transfer to cartilage 
defects can be achieved by either direct vector administration 
to cells located at or surrounding the defects, or by 
transplantation of genetically modified chondrogenic cells 
into the defect [17]. 
CLINICAL EXPERIENCE WITH MESENCHYMAL 
STEM CELLS 
  Mesenchymal stem cells of bone-marrow stromal origin 
have been used in an attempt to produce articular cartilage in 
several animal models and compared with other techniques 
[18]. Cells have been combined with different matrices, such 
as Type I collagen gels or modified hyaluronan and different 
growth factors. Transforming growth factor- (TGF- ), 
BMP-2 and insulin growth factor-1 (IGF-1) are emerging 
among the most popular candidates shown to encourage 
chondrogenic differentiation of MSCs. There are limited 
human  in vivo studies at present. Comparison between 
studies is difficult as no single protocol has yet emerged as 
the best model for cartilage engineering from stem cells. 
Both two-step and one-step techniques have been developed 
as well as percutaneous methods of cell application. 
 Kuroda  et al. 2007 [14] treated a large full thickness 
articular cartilage defect in the femoral condyle of an athlete 
with autologous bone-marrow stromal cells. Bone marrow 
was aspirated from the patient’s iliac crest 4 weeks before 
surgery and the cells were expanded in culture after 
removing the erythrocytes. Cells were then embedded within 
a collagen gel which was transferred to the articular cartilage 
defect and covered with an autologous periosteal flap. Seven 
months after surgery, arthroscopy revealed the defect to be 
covered with smooth tissues. Histologically the defect was 
covered with a hyaline-like type of cartilage tissue. One year 
after surgery, the clinical symptoms had improved 
significantly and the patient had returned to his previous 
activity level. 
 Gianinni  et al. [19] have developed a one-step repair 
technique with bone-marrow-derived cells. They have 
reported good clinical results in both the ankle and knee [19, 
20]. As well as bone marrow aspiration, the technique 
involves creating a platelet-rich fibrin gel from a sample of 
the patient’s own blood. The bone marrow is concentrated by 
centrifugation and implanted onto a hyaluronic acid 
membrane which is then placed surgically into the cartilage 
defects and covered with the platelet-rich gel. Wakitani et al. 
[21] reported on three knee cases using undifferentiated bone 
marrow derived MSC associated with a collagen sheet to 
repair chondral defects. They showed an improvement in 
IKDC (International Knee Documentation Committee) 
however in two patients they identified a fibrocartilage like 
tissue in the defect similar to their previous study [14]. This 
suggests that autologous stem cells do not always 
differentiate into mature hyaline cartilage. Haleem et al. [22] 
have used MSCs transplanted on a scaffold of platelet-rich 
fibrin glue (PR-FG) in the treatment of articular cartilage 
defects in the knees of 5 patients. Symptoms and knee scores 
improved in all patients. Platelet-rich fibrin glue may be an 
ideal MSC scaffold as the -secretory granules of platelets 
contain both TGF-1 and IGF-1 [23-26]. 
 
  Overall the results achieved using bone-marrow stromal 
cells have been similar to those yielded using other cell-
matrix systems, the repair tissue formed being principally 
fibrocartilaginous in nature, but of variable quality and 
durability [4]. 
FUTURE DIRECTIONS 
  In order to engineer cartilage with stem cells researchers 
must control many factors, including differentiation and 
cartilage matrix synthesis, particularly collage II production. 
Because cartilage is a primarily avascular tissue a relatively 
hypoxic environment is created. It has been postulated that 
this hypoxia is important for chondrogenesis and 
consequently in vitro engineering efforts have attempted to 
mimic this environment generally showing enhancement of 
chondrogenesis. Hypoxic conditions have been shown to 
significantly alter the chondrogenic differentiation process 
whereby cells cultured in these conditions had an enhanced 
ability to produce collagen type II and glycosaminoglycans. 
This resulted in better biomechanical functionality in 
artificial cell constructs [29]. 
  We have previously showed that bone marrow derived 
MSCs undergoing chondrogenic differentiation exhibit a 
greatly enhanced induction of chondrogenesis under hypoxic 
conditions (5% oxygen) as compared to normoxic culture 
conditions (20% oxygen). Changes in gene expression 
suggesting enhanced chondrogenesis were apparent in lower 
oxygen conditions, and there was greater staining for 
collagen type II (Fig. 1) [30]. A similarly enhanced 
chondrogenic response was seen when we cultured 
infrapatellar fat pad (IPFP) derived stem cells under 
conditions of low oxygen tension (Fig. 2) [31]. We have also 
showed that chondrogenic differentiation is potentiated by 
FGF-2 supplemented expansion of infrapatellar fat pad 
(IPFP) derived cells. The effect of FGF-2 expansion was 
quantified by a greater increase in collagen type II 
expression, as compared to non-FGF-2-expanded cells, and 
this was confirmed on immunohistochamistry. The IPFP 
cells were shown to have capacity for multidifferentiation by 
3G5 staining for pericytes, which are known to have such a 
potential [32]. 
  However the actual differentiation of mesenchymal stem 
cells into chondrocytes may not be of paramount importance. 
MSCs have been proposed as a natural system for tissue 
repair [27]. They have been shown to seemingly enhance the 
repair of damaged tissue when applied exogenously in a 
variety of experimental models. However in the vast 
majority of these studies the therapeutic efficacy did not 
correlate with the efficiency of engraftment, which was in 
general low. These findings suggest that the ability to repair 
was very likely secondary not only to the differentiation of 
the cells into the appropriate phenotype, but by the secretion 
of soluble factors that altered the tissue microenvironment. 
In other words stem cells may have a trophic effect on 
injured tissues. Research has shown that MSCs in vitro 
produce a variety of factors that influence a broad range of 
biological functions, including angiogenesis, and also secrete 
neuroregulatory peptides and cytokines with critical roles in 
inflammation and repair [28]. 
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  Ultimately large scale clinical trials are needed to 
evaluate the effectiveness and safety of MSC therapy in the 
treatment of cartilage defects. Over a 100 clinical trials 
utilizing exogenous bone marrow derived stem cells to treat 
a wide variety of conditions are registered with 
ClinicalTrials.gov [33, 34]. Although many are investigating 
stem cell use in orthopaedic associated tissue regeneration, 
limited evidence is currently available to support routine use. 
 
Fig. (1). Immunohistochemistry of chondrogenic cultures of bone marrow derived MSCs. Immunohistochemical staining for collagen type I 
and II, aggrecan and control IgG in cell aggregates following chondrogenic differentiation for 14 days under normoxic and hypoxic culture 
conditions [30]. 300    The Open Orthopaedics Journal, 2011, Volume 5  Punwar and Khan 
  There is no doubt that mesenchymal stem cells are 
readily available from a number of sources and they clearly 
have the ability to regenerate damaged mammalian tissues. 
However further research is needed to elucidate exactly how 
they exert their reparative actions. It may be that a 
revolutionary new field of MSC medicine will emerge, 
augmenting the normal healing process of injured tissues 
[35]. The potential therapeutic possibilities appear endless. 
 Centeno  et al. [29] have injected bone marrow-derived stem cells percutaneously into the knee of a patient with 
radiographic signs of degenerative joint disease. Six months later they observed a significant cartilage growth and pain was 
improved. These findings may support the injection of MSCs directly into joints against filling up cartilage defects with 
complex engineered scaffolds. 
 
Fig. (2). Immunohistochemical staining in chondrogenic cultures of infrapatellar fat pad derived MSCs. Immunohistochemical staining for 
collagen type I and II, aggrecan and control IgG in cell aggregates following chondrogenic differentiation for 14 days under normoxic and 
hypoxic culture conditions [31]. Stem Cells and Cartilage Repair  The Open Orthopaedics Journal, 2011, Volume 5    301 
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